for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up
Company News

BRIEF-MEDICENNA UPDATES ON-GOING PHASE 2B CLINICAL TRIAL PROTOCOL FOR RECURRENT GLIOBLASTOMA

Sept 28 (Reuters) - Medicenna Therapeutics Corp:

* MEDICENNA UPDATES ON-GOING PHASE 2B CLINICAL TRIAL PROTOCOL FOR RECURRENT GLIOBLASTOMA

* AMENDED PROTOCOL INCORPORATES AN ENHANCED DRUG DELIVERY PROCEDURE WHICH WILL BE USED FOR TREATMENT OF REMAINING PATIENTS

* COMMENCED IMPLEMENTATION OF UPDATED PROTOCOL FOLLOWING ITS SUBMISSION TO FDA & APPROVAL BY RESPECTIVE INSTITUTIONAL REVIEW BOARDS

* UPDATED PROTOCOL INCLUDES HIGHER DOSES AND VOLUMES OF MDNA55

* EARLY RESULTS FROM INTERIM SAFETY ANALYSIS INDICATES CURRENT DOSE OF MDNA55 BEEN WELL TOLERATED IN INITIAL COHORT OF PATIENTS

* PROTOCOL AMENDMENT BASED ON PLANNED SAFETY ANALYSIS FOLLOWING UNANIMOUS RECOMMENDATION FROM MDNA55’S SAFETY REVIEW COMMITTEE

* SEES ENROLLMENT TO BE COMPLETED BY EARLY 2018, WITH INTERIM TOP-LINE RESULTS EXPECTED DURING FIRST HALF OF 2018 FOR MDNA55

* UPDATED PROTOCOL INCLUDES INCREASE IN TOTAL EXPECTED STUDY SIZE FROM 43 PATIENTS TO 52 TOTAL PLANNED PATIENTS

* IN AMENDMENT OF PROTOCOL, PRIMARY ENDPOINT OF STUDY REMAINS SAME

* BASED ON EXCEPTIONAL SAFETY PROFILE, CONCENTRATION OF MDNA55 WILL BE DOUBLED TO 3.0 MG/ML

* BASED ON EXCEPTIONAL SAFETY PROFILE, VOLUME ADMINISTERED WILL BE MAXIMIZED TO A FIXED VOLUME OF 60ML Source text for Eikon: Further company coverage:

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up